Nightingale Clinical Trial

Description

This is a randomized prospective observational study intended to show the clinical utility of the Percepta Nasal Swab in patients with a new lung nodule and a history of smoking. The test is designed to help to stratify the risk of primary lung cancer in both screening-identified and incidental nodules. The swab is a simple, office-based collection that involved a single, brief brushing of the nasal epithelium and employs RNA whole transcriptome sequencing. The test is run by a CLIA lab and is intended to help patients with benign nodules avoid unnecessary invasive procedures while optimizing the time to diagnosis and treatment for those with primary lung cancer.

Official Title

NIGHTINGALE: Clinical Utility of Management of Patients with CT and LDCT Identified Pulmonary Nodules Using the Percepta Nasal Swab Classifier

Eligibility

You can join if you:

• have a new pulmonary nodule ≤ 30 mm
• are between the ages of 29 and 85
• have a smoking history of ≥ 100 cigarettes smoked in a lifetime
• have no history of prior lung cancer

Location

114 Woodland Street, Hartford, CT 06105

Principal Investigator

Anil Magge, M.D.

Anil Magge, MD, is an Interventional Pulmonologist for the Department of Pulmonary, Critical Care, and Sleep Medicine at Saint Francis Hospital with Trinity Health Of New England Medical Group.

Dr. Magge completed an Interventional Pulmonology Fellowship through the Combined Harvard Interventional Pulmonology Fellowship Program at Beth Israel Deaconess Medical Center and Massachusetts General Hospital in Boston, Massachusetts, where he was trained in several subspecialty areas including malignant and benign central airway disease, lung nodules and masses, COPD and emphysema, and pleural disease. He gained expertise in advanced diagnostic and therapeutic airway procedures including rigid and flexible bronchoscopy, tumor debulking, and airway stenting. Additionally, he became skilled in robotic bronchoscopy, endobronchial valve placement, medical thoracoscopy and other minimally invasive procedures of the airway, esophagus, and pleura. He is currently involved in multiple research projects and plans to bring clinical trials and cutting-edge technology for the diagnosis and treatment of lung cancer to Saint Francis Hospital.

Dr. Magge obtained his Doctor of Medicine degree from the University of Connecticut School in Farmington, Connecticut. He then continued his training at the University of Connecticut where he completed an Internship and Residency in Internal Medicine and was chosen and served as the Chief Medical Resident. He then completed a Pulmonary and Critical Care Fellowship at the University of Connecticut. During his fellowship he was name the Teaching Fellow of the Year in 2019-20 and was inducted into Alpha Omega Alpha Honor Medical Society.